EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Alternative MYB Promoter Activity Is a Potential Prognostic Biomarker in Head and Neck Adenoid Cystic Carcinoma

Fredrik Jäwert, André Fehr, Marta Persson, Adel K El-Naggar, Göran Stenman, Mattias K Andersson iD

Head & Neck · 2025-07 · 47 (7) · 1996-2002

DOI: 10.1002/hed.28123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, online erschienen am 25.02.2025. Verfasst von Fredrik Jäwert und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Carcinoma, Adenoid Cystic, Head and Neck Neoplasms, Promoter Regions, Genetic, Proto-Oncogene Proteins c-myb. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Swedish state under an agreement between the Swedish government and country councils - the ALF agreement, Stiftelsen Assar Gabrielssons Fond, Cancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adenoid cystic carcinoma (ACC) is an aggressive therapy‐resistant head and neck cancer with a high frequency of local recurrences and distant metastases. Activation of the MYB gene, encoding an oncogenic master transcription factor, is the key genomic hallmark of ACC and a potential therapeutic target. Here, we have investigated the clinical significance of alternative MYB promoter ( MYB TSS2) activation in primary ACCs.

Methods

MYB TSS2 activity was studied in 28 ACCs using MYB exon‐specific qPCR assays. Overall survival (OS) and risk analyses were done to estimate the outcomes of MYB TSS2 high and low cases, respectively. The genomic and transcriptomic profiles of the ACCs were also analyzed in relation to MYB TSS2 activity.

Results

OS was significantly shorter among patients in the MYB TSS2 high group compared to the MYB TSS2 low group ( p = 0.02). Multivariate analysis indicated that MYB TSS2 activity was a significant prognostic biomarker for OS ( p = 0.03) that was independent of tumor grade and NOTCH1 mutation status. There was markedly higher MYB TSS2 activity in ACCs with 6q deletions compared to those without deletions ( p = 0.04). Moreover, MYB TSS2 high tumors had an increased expression of cell cycle genes and known MYB target genes.

Conclusion

The study demonstrates that alternative MYB promoter activity is a new potential prognostic biomarker for ACC and further strengthens the relevance of MYB‐targeted therapy. Our findings indicate that MYB TSS2 high primary tumors are more aggressive and have a worse prognosis than MYB TSS2 low tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Adenoid CysticHead and Neck NeoplasmsPromoter Regions, GeneticProto-Oncogene Proteins c-mybGenes, mybHumansMaleFemaleMiddle AgedPrognosisAgedBiomarkers, TumorAdultGene Expression Regulation, NeoplasticSurvival Analysis

Stichwörter der Autor:innen

MYBTSS2adenoid cystic carcinomaalternative promoterprognostic biomarkersalivary gland

Substanzen

Biomarkers, TumorMYB protein, humanProto-Oncogene Proteins c-myb

Autor:innen und Institutionen

  • Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, University of Gothenburg, Gothenburg, Sweden.
  • Department of Otorhinolaryngology, Oral and Maxillofacial Surgery, Region Västra Götaland, NU-Hospital Group, Trollhättan, Sweden.
  • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Mattias K Andersson

Förderung

  • The Swedish state under an agreement between the Swedish government and country councils - the ALF agreement
  • Stiftelsen Assar Gabrielssons Fond
  • Cancerfonden
  • The Sjöberg Foundation
  • Sjöbergstiftelsen

Zitieren

APA

Jäwert, F., Fehr, A., Persson, M., El-Naggar, A. K., Stenman, G., & Andersson, M. K. (2025). Alternative MYB Promoter Activity Is a Potential Prognostic Biomarker in Head and Neck Adenoid Cystic Carcinoma. Head & Neck, 47(7), 1996-2002. https://doi.org/10.1002/hed.28123

Vancouver

Jäwert F, Fehr A, Persson M, El-Naggar AK, Stenman G, Andersson MK. Alternative MYB Promoter Activity Is a Potential Prognostic Biomarker in Head and Neck Adenoid Cystic Carcinoma. Head & Neck. 2025;47(7):1996-2002. doi:10.1002/hed.28123

BibTeX
@article{Jwert2025,
  author = {Jäwert, Fredrik and Fehr, André and Persson, Marta and El-Naggar, Adel K and Stenman, Göran and Andersson, Mattias K},
  title = {Alternative MYB Promoter Activity Is a Potential Prognostic Biomarker in Head and Neck Adenoid Cystic Carcinoma},
  journal = {Head & Neck},
  year = {2025},
  volume = {47},
  number = {7},
  pages = {1996--2002},
  doi = {10.1002/hed.28123}
}
Kostenlos starten →